Promoter for expression of stimulus-induced gene in t cell

The NFAT-NR4A promoter combination enhances T cell stimulation-dependent protein expression, addressing the limitations of existing promoters by achieving sustained and targeted protein production in CAR-T cells, thus improving therapeutic efficacy.

WO2024241419A1PCT designated stage expired Publication Date: 2024-11-28HITACHI LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2023/018919
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current gene expression promoters, such as NFAT and NR4A, have limited activity and specificity, making them insufficient for therapeutic protein production in T cells, particularly in CAR-T cell therapies, where sustained and targeted protein expression is needed.

Method used

A stimulation-inducible gene expression promoter is developed by linking NFAT binding sequences with NR4A binding sequences and a minimal promoter, enhancing activity strength while maintaining specificity, allowing for prolonged and increased protein production in T cells upon stimulation.

Benefits of technology

The combined promoter significantly increases protein expression in T cells, particularly in CAR-T cells, with sustained activity over time and targeted antigen-dependent expression, improving the efficacy of protein-based therapies like antibody and cytokine treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2023018919_28112024_PF_FP_ABST
    Figure JP2023018919_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a polynucleotide comprising a promoter having an NFAT-binding sequence and an NR4A-binding sequence. The invention also relates to a vector comprising the polynucleotide, a cell comprising the vector, and a pharmaceutical composition comprising the polynucleotide, the vector, or the cell. The present invention also relates to a method for producing a genetically modified cell, the method involving introducing the polynucleotide into a T cell.
Need to check novelty before this filing date? Find Prior Art

Description

Stimulation-inducible gene expression promoter in T cells

[0001] The present invention relates to a promoter for stimulus-inducible gene expression in T cells, and more specifically to a polynucleotide comprising a promoter having an NFAT-binding sequence and an NR4A-binding sequence. The present invention further relates to a vector comprising the polynucleotide, a cell comprising the vector, and a pharmaceutical composition comprising the polynucleotide, the vector, or the cell. The present invention also relates to a method for producing a genetically modified cell, a method for producing the promoter, and a method for expressing a protein using the promoter, each of which comprises the step of introducing the polynucleotide into a T cell.

[0002] In recent years, a number of therapeutic methods using genetically modified T cells with enhanced function, such as chimeric antigen receptor (CAR) T cells, have been approved. Therefore, the development of genetic modification strategies aimed at adding additional functions to T cells has become active. In particular, the development of mechanisms that induce T cells to produce and release proteins is expected to reduce side effects by limiting the range of action in the body while maintaining the efficacy of conventional protein-based therapies such as antibody drugs and cytokine therapy.

[0003] Among the mechanisms for causing T cells to produce proteins, the NFAT promoter has been used as a mechanism for causing T cells to produce proteins only when activated (Patent Document 1, Non-Patent Documents 1 and 2). The NFAT promoter is known to be activated and can induce the expression of downstream genes only when T cells recognize a target antigen via a T cell receptor (TCR) or CAR.

[0004] Furthermore, the NR4A promoter has been reported as a type of promoter responsive to T cell stimulation (Non-Patent Document 3).

[0005] Special Publication No. 2021-523743

[0006] Molecular Therapy, Vol.19, No.4, 751-759, 2011Molecular Therapy Oncolytics, Vol.12, p.16-25, March 29, 2019ACS Synth. Biol. 2022, 11, 1440-1453

[0007] The NFAT promoter is highly responsive to stimuli, highly specific to those stimuli, and has low activity in the absence of stimuli, making it useful in basic research for detecting T cell activation. However, because the activity of the promoter, i.e., the amount of protein encoded by the downstream gene produced, is low, it has been considered insufficient for use in producing therapeutic proteins.

[0008] Furthermore, since the NR4A promoter also has limitations in promoter activity, further improvements to the promoter and enhancement of protein production by T cells were needed.

[0009] The present inventors have modified the promoter sequence to improve the activity of a T cell stimulation-responsive promoter. Specifically, after examining various combinations of T cell stimulation-responsive promoters, they have found a promoter that retains the stimulation specificity of the NFAT promoter while enhancing its activity by linking an NFAT-binding sequence with an NR4A-binding sequence.

[0010] That is, the present invention provides a polynucleotide comprising a promoter having an NFAT-binding sequence and an NR4A-binding sequence.

[0011] The present invention provides a promoter that can induce protein expression in a T cell stimulation-dependent manner, has enhanced activity without losing promoter specificity, and has activity that lasts for a longer period of time. Longer-lasting activity results in greater amounts of protein production.

[0012] 1 shows an example of the promoter structure of the present invention. The NFAT promoter (NFATp) contains three NFAT-binding sequences (NFAT-RE) together with an IL2 minimal promoter. The NR4A promoter (NR4Ap) contains eight NR4A-binding sequences (NR4A-RE) together with a synthetic minimal promoter (SEQ ID NO: 6). The NFAT-NR4A promoter (NNp) has a structure in which, from upstream to downstream, eight NR4A-binding sequences, three NFAT-binding sequences, and an IL2 minimal promoter are linked. GOI: gene of interest (gene of interest) whose expression is controlled by the promoter. An example of a vector containing a promoter of the present invention (NNp-GFP-EF1p-puro, SEQ ID NO: 17) is shown. The expression level of CAR in cells transfected with vectors containing the three promoters used in Example 1 (A: SEQ ID NO: 15, B: SEQ ID NO: 16, C: SEQ ID NO: 17) is shown. The expression of GFP dependent on CAR stimulation from CAR-T cells transfected with vectors containing the three promoters is shown. NFAT-IL2minP: NFAT promoter; NR4A-SMP: NR4A promoter; NN-IL2miniP: promoter of the present invention; No Target: without Nalm cells; w / Nalm: co-culture with Nalm cells. The graph shows the expression level of CAR in cells transfected with vectors containing two promoters (A: SEQ ID NO: 15; B: SEQ ID NO: 17). The graph shows CAR stimulation-dependent GFP expression from CAR-T cells using the promoter of the present invention (NR4A-NFAT) and a conventional NFAT promoter (NFAT). Vertical axis: activity intensity; horizontal axis: ratio of CAR-T cells to target cells. A: 24 hours later; B: 48 hours later; C: 72 hours later. An example of a vector containing the promoter of the present invention (NNp-IL12-SFFVp-CAR-mCherry, SEQ ID NO: 23) is shown. CAR-T cells (denoted as YC) transfected with three promoters (NFATp-IL12p40, NR4Ap-IL12p40, and NNp-IL12p40) linked to the IL12p40 coding sequence were shown to express IL12p40 in a CAR-T cell-dependent manner. WT: wild-type Nalm cells; CD19KO: CD19-deficient Nalm cells; -: no Nalm cells.CAR stimulation-dependent etanercept expression from CAR-T cells (denoted as YC) transfected with three promoters (NFATp-Etanercept, NR4Ap-Etanercept, and NNp-Etanercept) linked to the etanercept coding sequence is shown in terms of TNFα inhibitory activity. NNp-Anakinra: The promoter of the present invention linked to the anakinra coding sequence. WT: wild-type Nalm cells; CD19KO: CD19-deficient Nalm cells; -: no Nalm cells. CAR stimulation-dependent anakinra expression from CAR-T cells transfected with three promoters (NFATp-Anakinra, NR4Ap-Anakinra, and NNp-Anakinra) linked to the anakinra coding sequence is shown in terms of IL-1β inhibitory activity. NNp-Etanercept: The promoter of the present invention linked to the etanercept coding sequence. WT: wild-type Nalm cells, CD19KO: CD19-deficient Nalm cells, -: no Nalm cells.

[0013] Hereinafter, embodiments of the present invention will be described in detail, but the present invention is not limited to these descriptions, and various modifications can be made by those skilled in the art within the scope of the technical ideas disclosed in this specification.

[0014] The present invention provides a polynucleotide comprising a promoter having an NFAT-binding sequence and an NR4A-binding sequence. The promoter further comprises a minimal promoter containing a sequence region called a TATA box, which serves as an origin of mRNA synthesis by RNA polymerase II. The minimal promoter may be, but is not limited to, a naturally occurring promoter such as the IL2 minimal promoter, or a synthetic minimal promoter.

[0015] NFAT (Nuclear factor of activated T-cells) is a family of transcription factors that are important in immune responses and are known to be expressed in most cells of the immune system. An NFAT-binding sequence is a sequence known to bind to NFAT, and includes, but is not limited to, the nucleotide sequence shown in SEQ ID NO: 1 (ggaggaaaaactgtttcatacagaaggcgt) or its core sequence, ggaaaa (SEQ ID NO: 2). NFAT-binding sequences also include complementary sequences of the nucleotide sequences shown in SEQ ID NO: 1 or SEQ ID NO: 2. Conventionally known NFAT promoters consist of a nucleotide sequence containing multiple sequences to which the transcription factor NFAT binds, and a minimal promoter.

[0016] Similarly, an NR4A promoter has been reported, which is composed of a nucleotide sequence in which multiple sequences to which the transcription factor NR4A (Nuclear Receptor 4A) binds and a minimal promoter (ACS Synth. Biol. 2022, 11, 1440-1453). Examples of NR4A-binding sequences include, but are not limited to, the nucleotide sequence shown in aaaggtcac (SEQ ID NO: 3) or its core sequence, aaaggtca (SEQ ID NO: 4). Other examples of NR4A-binding sequences include complementary sequences of the nucleotide sequences shown in SEQ ID NO: 3 or SEQ ID NO: 4.

[0017] For example, in the polynucleotide of the present invention, it is preferred that the NFAT-binding sequence is the nucleotide sequence shown in SEQ ID NO: 1 or 2, or a complementary sequence thereof, and the NR4A-binding sequence is the nucleotide sequence shown in SEQ ID NO: 3 or 4, or a complementary sequence thereof. More preferably, in the polynucleotide of the present invention, the NFAT-binding sequence is the nucleotide sequence shown in SEQ ID NO: 1 or a complementary sequence thereof, and the NR4A-binding sequence is the nucleotide sequence shown in SEQ ID NO: 3 or a complementary sequence thereof.

[0018] In the polynucleotide of the present invention, the order in which the NFAT-binding sequence and the NR4A-binding sequence are linked is not particularly limited. For example, the NR4A-binding sequence may be linked upstream of the NFAT-binding sequence, or the NR4A-binding sequence may be linked downstream of the NFAT-binding sequence. A minimal promoter may be linked downstream of the NFAT-binding sequence and a gene whose expression is intended to be induced may be linked downstream of the minimal promoter. In one embodiment, the polynucleotide of the present invention may have an NR4A-binding sequence upstream of the NFAT-binding sequence.

[0019] The NFAT-binding sequence and the NR4A-binding sequence may be directly linked, or may be linked with an interval of several bases, for example, 1 to 100 bases, for example, 5 to 80 bases, 10 to 70 bases, or 20 to 60 bases. Similarly, the minimal promoter may be directly linked to the NFAT-binding sequence or the NR4A-binding sequence, or may be linked with an interval of several bases, for example, 1 to 10 bases.

[0020] In a preferred embodiment, the polynucleotide of the present invention can comprise multiple NFAT-binding sequences, for example, 3 to 6 repeats of the NFAT-binding sequence, and multiple NR4A-binding sequences, for example, 6 to 10 repeats of the NR4A-binding sequence. Repeating the binding sequences increases the potency of activity, but including more binding sequences than the above range is unlikely to further increase the potency of activity. Furthermore, there is a limit to the size of the polynucleotide that can be carried by a vector, so it is preferable to keep the number of sequences within the above range. In a preferred embodiment, the polynucleotide of the present invention can comprise three NFAT-binding sequences and eight NR4A-binding sequences. The multiple NFAT-binding sequences contained in the polynucleotide of the present invention do not have to have the same nucleotide sequence; as described above, the nucleotide sequence shown in SEQ ID NO: 1 or 2, or a complementary sequence thereof, may be present in the polynucleotide of the present invention. Similarly, the multiple NR4A-binding sequences contained in the polynucleotide of the present invention do not have to have the same nucleotide sequence; as described above, the nucleotide sequence shown in SEQ ID NO: 3 or 4, or a complementary sequence thereof, may be present in the polynucleotide of the present invention.

[0021] As described above, the polynucleotide of the present invention can have a gene encoding a protein downstream of the promoter. The promoter of the present invention can increase the production of the protein encoded by the downstream gene in a T cell stimulation-dependent manner.

[0022] In the present invention, the protein whose expression is intended to be increased is not particularly limited, and may be selected from the group consisting of, for example, cytokines, chemokines, growth factors, antibodies, agonists, antagonists, neuropeptides, and transcription factors.

[0023] For example, inflammation may occur due to an increase in the release of undesirable cytokines associated with the activation of T cells, such as CAR-T cells. Thus, the polynucleotides of the present invention may induce the expression of proteins whose increased expression is desired in association with T cell activation.

[0024] Cytokines whose expression is contemplated to be increased include, for example, interferons (e.g., α-interferon, β-interferon, γ-interferon), interleukins (e.g., IL-1, IL-1a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-17A, IL-18, IL-19, IL-20, IL-24), tumor necrosis factors (e.g., TNF-α), transforming growth factor β, TRAIL, and flexi-12, a single polypeptide chain comprising two polypeptide chains of the IL-12 heterodimer (Anderson et al. (1997) Hum. Gene Ther. 8:1125); and IL-12 superkine H9.

[0025] Chemokines whose expression is intended to be increased include, for example, MIP-1, MIR-I b, MCP-1, RANTES, IP10, chemokine (C-C motif) ligand-2 (CCL2), chemokine (C-C motif) ligand-3 (CCL3), chemokine (C-C motif) ligand-5 (CCL5), chemokine (C-C motif) ligand-17 (CCL17), chemokine (C-C motif) ligand-19 (CCL19), chemokine (C-C motif) ligand-21 (CCL21), CC chemokine receptor type 7 (CCR7), chemokine (C-X-C motif) ligand 9 (CXCL9), chemokine (C-X-C motif) ligand 10 (CXCL10), chemokine (C-X-C motif) ligand 11 (CXCL11), and chemokine (C-X-C motif) ligand 16. (CXCL16), chemokine (C motif) ligand (XCL1), and macrophage colony-stimulating factor (MCSF).

[0026] Examples of growth factors whose expression is intended to be increased include hepatocyte-stimulating factor, plasmacytoma growth factor, brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), neurotrophic factor 3 (NT3), fibroblast growth factor (FGF), transforming growth factor (TGF), platelet-transforming growth factor, mammary growth factor, endothelial growth factor (EGF), endothelial cell-derived growth factor (ECDGF), α-endothelial growth factor, β-endothelial growth factor, neurotrophic growth factor, nerve growth factor (NGF), vascular endothelial growth factor (VEGF), 4-1BB receptor (4-1BBR), TNF-related apoptosis-inducing ligand (TRAIL), artemin (GFRalpha3-RET ligand), B-cell-attracting chemokine 1 (BCA-1), B-lymphocyte chemoattractant (BLC), B-cell maturation protein (BCMA), bone growth factors such as osteoprotegerin (OPG), bone-derived growth factor, and megakaryocyte-derived growth factor. Examples of such factors include granulocyte-macrophage colony-stimulating factor (MGDF), keratinocyte growth factor (KGF), thrombopoietin, platelet-derived growth factor (PGDF), neurotrophin-2 (NT-2), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), neurotrophin-5 (NT-5), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), bone morphogenetic protein 2 (BMP2), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte-colony-stimulating factor (G-CSF), macrophage-colony-stimulating factor (M-CSF), and colony-stimulating factor (CSF).

[0027] Antibodies, agonists, and antagonists whose expression is intended to be increased include, for example, natalizumab, vedolizumab (MLN2), belimumab, atacicept, alefacept, otelixizumab, teplizumab, rituximab, ofatumumab, ocrelizumab, epratuzumab, alemtuzumab, abatacept, eculizumab, omalizumab, canakinumab, mepolizumab, and reslizumab. (SCH55700), tocilizumab, ustekinumab, briakinumab, etanercept, infliximab, adalimumab, certolizumab pegol, golimumab, ipilimumab, tremelimumab, nivolumab, MK-3475, pidilizumab, BMS-936559, MEDI4736, MPDL33280A, ibritumomab tiuxetan, tositumomab, brentuximab vedotin, gemtuzumab ozogamicin, IGN101, adecatumumab, labetuzumab, huA33, pemtumomab, oregovomab, CC49 (minletumomab), cG250, J591, MOvl8, MORAb-003 (farletuzumab), 3F8, chl4.18, KW-2871, hu3S193, IgN31 1, bevacizumab, IM-2C6, CDP791, etaracizumab, volociximab, cetuximab, panitumumab, nimotuzumab, trastuzumab, pertuzumab, MM-121, AMG 102, METMAB, SCH 900105, AVE1642, IMC-A12, MK-0646, R1507, CP 751871, KB004, IIIA4, mapatumumab (HGS-ETR1), HGS-ETR2, CS-1008, denosumab, sibrotuzumab, F19, 81C6, blinatumomab, pembrolizumab, 9E10 antibody, and the like.

[0028] Neuropeptides whose expression is intended to be increased include, for example, N-acetylaspartylglutamate, agouti-related peptide, α-endorphin, dynorphin, bombesin, bombesin-like peptide, carbetocin, and cocaine- and amphetamine-regulated transcripts. Examples of such proteins include (CART), cholecystokinin, corazonin, corticotropin-like intermediate peptide, cortistatin, demoxytocin, eledoisin, enkephalin, galanin, galanin-like peptide, analgesic peptide, galnon, gamma-endorphin, ghrelin, hemopressin, kisspeptin, neurokinin B, neuromedin B, neuromedin N, neuromedin S, neuromedin U, neuromedin S, neuromedin Y, neuropeptide Y, neurotensin, nociceptin, opiorphin, orexin, orexin-A, oxytocin, physalamin, preprotachykinin, proctolin, proenkephalin, proopiomelanocortin, relaxin-3, somatostatin, substance P, TAC1, tachykinin, vasopressin, and vasotocin.

[0029] Examples of transcription factors whose expression is intended to be increased include ABT1, ACYP2, AEBP1, AEBP2, AES, AFF1, AFF3, AHR, ANK1, ANK2, ANKFY1, ANKIB1, ANKRD1, ANKRDIO, ANKRD2, ANKRD32, ANKRD46, ANKRD49, ANKRD56, ANKRD57, ANKS4B, AR, ARHGAP17, ARID1A, ARIDIB, ARID3A, ARID4A, ARID5B, ARNT, ARNT2, ARNTL, ARNTL2, ARX, ASB10, ASB11, and ASB12. , ASB15, ASB2, ASB5, ASB8, ASB9, ASH1L, ASH2L, ASXL1, ASZ1, ATF1, ATF3, ATF4, ATF4, ATF5, ATF6, ATF7, ATF7IP, ATM, ATOH1, ATXN3, 1300003B13RIK, B3G AT3, B930041F14RIK, BACH1, BACH2, BARX1, BARX2, BATF, BATF2, BATF3, BAZ2A, BBX, BC003267, BCL11A, BCL11B, BCL3, BCL6, BCL6B, BCLAF1, BCOR, BHLHA 15, BHLHE40, BHLHE41, BLZF1, BMYC, BNC1, BNC2, BPNT1, BRCA1, BRWD1, BTBD11, BTF3, 6030408C04RIK, CAMK4, CARHSP1, CARM1, CBX4, CBX7, CCNC, CCNH, CCNT1, CCNT2, CDC5L, CDK2, CDK4, CDK9, CDKN2C, CDX1, CDX1, CDX2, CEBPA, CEBPB, CEBPD, CEBPG, CEBPG, CEBPZ, CHD4, CHD7, CHGB, CIC, CIITA, CITED1, CI TED2, CITED4, CLOCK, CLPB, CML3, CNOT7, COPS2, CREB1, CREB3, CREB3L1, CREB3L1, CREB3L2, CREB3L3, CREB5, CREBBP, CREBL2, CREM, CSDA, CSDA, CSDC2, CSDE1, CTBP2, CTCF, CTCFL, CTNNB1, CTNNBL1, CXXC1, D11BWG0517E, 2300002D11RIK, DACH1, DAXX, DBP, DDIT3, DDX20, DDX54, DDX58, DEAF1, DEK, DIDOl,DLX2, DMRT1, DMRT2, DMRTB1, DNMT1, DNMT3A, DR1, DRG1, DUSP26, DYSFIP1, E2F1, E2F2, E2F3, E2F5, E2F6, EBF1, EBF2, EBF3, EBF3, EED, EGR1, EGR2, EGR3, EHF, EHMT2, EID2, ELAVL2, ELF1, ELF1, ELF2, ELF3, ELF4, ELF5, ELK3, ELK4, ELL2, EMX2, EMX2, EN2, ENPP2, EOMES, EP300, EPAS1, ERF, ERG, ESR1, ESRRA, E SRRB、ESRRG、ETS1、ETS2、ETV1、ETV3、ETV4、ETV5、ETV6、EVI1、EWSR1、EZH1、EZH2、FAH、FBXL10、FBXL11、FBXW7、FEM1A、FEM1B、FEM1C、FHL2、FL、FMNL2、FO S、FOSB、FOSL1、FOSL2、FOXA1、FOXA2、FOXA3、FOXC1、FOXD1、FOXD2、FOXD3、FOXF1、FOXFIA、FOXF2、FOXGl、FOXIl、FOXJ2、FOXJ3、FOXKl、FOXK2、FOXLl、FOX L2, FOXM1, FOXN1, FOXN2, FOXN3, FOXOl, FOX03, FOXP1, FOXP2, FOXP3, FOXP4, FOXQl, FUS, FUSIPl, 2810021G02RIK, GABPA, GABPBl, GARNLl, GAS7, GATA1, GATA2、GATA3、GATA4、GATA5、GATA5、GATA6、GBX2、GCDH、GCM1、GFI1、GFI1B、GLI2、GLI3、GLIS1、GLIS2、GLIS3、GLS2、GMEB1、GMEB2、GRHL1、GRHL2、GRHL3、 GRLF1、GTF2A1、GTF2B、GTF2E2、GTF2F1、GTF2F2、GTF2H2、GTF2H4、GTF2I、GTF2IRD1、GTF2IRD1、GZF1、HAND2、HBP1、HCLS1、HDAC10、HDAC11、HDAC2、HDAC5 、HDAC9、HELZ、HESl、HES4、HES5、HES6、HEXIMl、HEY2、HEYL、HHEX、HHEX、HICl、HIC2、HIF1A、HIF1AN、HIPK2、HIVEP1、HIVEP2、HIVEP2、HIVEP3、HLF、HLTF<h2 style=";text-align:left;direction:ltr">HLX、HMBOX1、HMG20A、HMGA2、HMGB2、HMGB3、HNF1B、HNF4A、HNF4G、HOMEZ、HOXA10、HOXA11、HOXA13、HOXA2、HOXA3、HOX H OXC5, HOXC6, HOXC8, HOXC9, HOXD8, HOXD9, HR, HSBP1, HSF2BP, HTATIP2, HTATSF1, HUWE1, 5830417I10RIK, ID1, ID2, ID3, IFNAR2, 1KBKB, 1KBKG, IKZF1, IKZF2, IKZF3, IKZF4, IL31RA, ILF3, INGl, ING2, ING3, ING4, INSMl, INTS12, IQWDl, IRFl, IRFl, IRF2, IRF3, IRF4, IRF5, IRF6, IRF7, IRF8, IRF8, IRF8, IRF1, IRF2, IRF3, IRF4, IRF5, IRF7, IRF8, IRF8, IRF1, IRF2, IRF3, IRF4, IRF5, IRF6, IRF7, IRF8, IRF8, IRF9, IRF10, IRF11, IRF12, IRF13, IRF14, IRF15, IRF16, IRF17, IRF18, IRF19, IRF20, IRF20, IRF21, IRF22, IRF30, IRF31, IRF32, IRF33, IRF34, IRF40, IRF41, IRF42, IRF43, IRF44, IRF50, IRF55, IRF56, IRF57, IRF58, IRF59, IRF60, IRF60, IRF61, IRF62, IRF63, IRF64, IRF65, IRF66, IRF67, IRF68, IRF69, IRF70, IRF70, IRF71, IRF72, IRF73, IRF74, IRF75, IRF76, IRF77, IRF78, IRF79, IRF80, IRF80, IRF80, IRF80, IRF80, IRF80, IRF80, IRF80, IRF80, IRF9 ... LF15、KLF16、KLF2、KLF3、KLF4、KLF5、KLF6、KLF7、KLF8、KLF9、KRR1、6330416L07RIK、L3MBTL2、LASS2、LASS4、LASS6、L BA1、LBH、LBX1、LCOR、LDB1、LDB2、LEF1、LHX1、LHX2、LHX5、 LIMD1、LIN28、LMO1、LM04、LMX1A、LSM11、LSM4、LYL1、90306 12M13RIK、1810007M 14RIK、363245 1O06RIK、MAF、MAFA、MAFB、MAFF、MAFG、MAFK、MAGED1、MAP3K12、MAPK1、MAPK3、MAPK8、MAPK8IP1、MAX、M AZ、MBD2、MCM2、MCM4、MCM5、MCM6、MCM7、MECOM、MECP2、MED12、MED8、MEF2A、MEF2B、MEF2C、MEF2D、MEIS 1、MEIS1、MEIS2、MEOX2、MESP2、<h2 style=";text-align:left;direction:ltr">MID1、MITF、MKI67IP、MKL1、MLL1、MLL3、MLLT10、MLLT3、MLX、MLXIP、MLXIPL 、MNT、MNX1、MPL、MSC、MSRB2、MSX2、MTA3、MTF1、MTF2、MTPN、MXD1、MXD4、MXI 1、MYB、MYBBP1A、MYBL2、MYC、MYCBP、MYCL1、MYCN、MYEF2、MYF6、MYNN、MYOCD 、MYOD1、MYOG、MYST3、MYST4、MYT1L、MZF1、NAB1、NAB2、NANOG、NARG1、NCOA1、 NCOA2、NCOA3" L2, NFIA, NFIA, NFIB, NFIC, NFIL3, NFIX, NFKB1, NFKB2, NFKBIB, NFKBIE, NFKBIZ, NFXl, NFXLl, NFYA, NFYB, NHLHl, NKX2-2, NKX2-3, NKX2-5, NKX2-6, NKX 6-2、NMI、NOTCHl、NOTCH2、NOTCH3、NOTCH4、NPASl、NPAS2、NPAS3、NROBl、NR 0B2、NR1D1、NR1D2、NR1H3、NR1H4、NR1I2、NR1I3、NR2C1、NR2C2、NR2E3、NR2F 1、NR2F2、NR2F6、NR3C1、NR3C2、NR4A1、NR4A2、NR4A3、NR5A1、NR5A2、NRARP、 NRIP1、NRIP2、NSBP1、NSD1、NUDT12、NULL、NUPR1、1700065O13RIK、OLIG1、OL IG2、ONECUT1、ONECUT2、ONECUT3、ORC2L、OSGIN1、OSR1、OSR2、OSTF1、OVOL1 、OVOL2、PAPOLA、PAPOLG、PAPPA2、PATZ1、PAWR、PAX2、PAX5、PAX6、PAX7、PAX8 、PAX9、PBX1、PBX2、PBX3、PBX4、PCBD1、PCGF6、PDCD11、PDLIM4、PDX1、PEG3、 PERI、PFDN1、PGR、PHF1、PHF10、PHF12、PHF13、PHF14、PHF20、PHF21A、PHF5A、PHF7、PHOX2A、PHOX2B、PIAS2、PIR、PITX1、PITX2、PKNOX1、PKNOX2、PLA2G6、PLAGL1、PLAGL2、PLRG1、PML、POGK、POLR2B、POLR2E、POLR2H、POLR3E、POLR3H、POLRMT、POU1F1、POU2AF1、POU2F1、POU2F2、POU3F2、POU3F3、POU3F3、POU5F1、POU6F1、PPARA、PPARD、PPARG、PPARGC1A、PPARGCIB、PPP1R12C、PPP1R13B、PPP1R16B、PPPIRIB、PPP2R1A、PPP3CB、PQBPl、PRDM1、PRDM14、PRDM15、PRDM16、PRDM2、PRDM4、PRDM5、PRDM6、PRDM8、PREB、PRKAR1A、PRKCBP1、PROX1、PRRX1、PRRX2、PSMC5、PSMD10、PSMD9、PTF1A、PTGES2、PURB、PWP1、RAB11A、RAB11B、RAB15、RAB18、RAB1B、RAB25、RAB8A、RAB8B、RAI14、RARA、RARB、RARG、RASSF7、RBI、RBBP7、RBL1、RBM14、RBM39、RBM9、RBPJ、RBPJL、RCOR2、REL、RELA、RELB、RERE、REST、REX04、RFC1、RFX1、RFX2、RFX3、RFX5、RFX7、RFX8、RHOX5、RHOX6、RHOX9、RIPK4、RNF12、RNF14、RNF141、RNF38、RNF4、RORA、RORB、RORC、RPS6KA4、RREB1、RSRC1、RUNX1、RUNX1T1、RUNX2、RUNX3、RUVBL1、RUVBL2、RXRA、RXRG、RYBP、SAFB2、SALL1、SALL2、SALL4、SAP30、SAP30BP、SATB1、SATB2、SCAND1、SCAP、SCRT2、SEC14L2、SERTAD1、SF1、SFPI1、SFRS5、SH3D19、SH3PXD2B、SHANK3、SHOX2、SHPRH、SIN3A、SIN3B、SIRT2、SIRT3、SIRT5、SIX1、SIX1、SIX2、SIX3、SIX4、SIX5、SKI、SMAD1、SMAD2、SMAD3、SMAD7、SMARCA1、<h2 style=";text-align:left;direction:ltr">SMARCA2、SMARCA5、SMARCB1、SMYD1、SNAI1、SNAI2、SNAPC2、SNAPC4、SNIP1、SOLH、SOX1、SOX10、SOX1 1、SOX12、SOX13、SOX15、SOX17、SOX18、SOX2、SOX21、SOX4、SOX5、SOX6、SOX7、SOX8、SOX9、SP1、SP110、 SP140L、SP2、SP3、SP4、SP6、SP8、SPDEF、SPEN、SPI1、SPIB、SQSTM1、SREBF1、SREBF2、SRF、SSBP2、SSBP 3、SSBP4、SSRP1、ST18、STAG1、STAT1、STAT2、STAT3、STAT4、STAT5A、STAT5B、STAT6、SUB1、SUZ12、TAD A2L, TAF13, TAF5, TAF5L, TAF7, TAF9, TALI, TARDBP, TBPL1, TBR1, TBX1, TBX10, TBX15, TBX18, TBX2, TBX20, TBX21, TBX3, TBX4, TBX5, TBX6, TCEA1, TCEA3, TCEAL1, TCEB3, TCERG1, TCF12, TCF15, TCF19, TC F20, TCF21, TCF3, TCF4, TCF7, TCF7L2, TCFAP2A, TCFAP2B, TCFAP2C, TCFCP2L1, TCFE2A, TCFE3, TCFEB, TCFEC, TCFL5, TEAD1, TEAD2, TEAD3, TEAD4, TEF, TFAP2A, TFAP2C, TFCP2L1, TFDP2, TFEB, TFEC, TGFB 111、TGIF1、TGIF2、TGIF2LX、THRA、THRAP3、THRB、THRSP、TIAL1、TLE1、TLE6、TMEM131、TMPO、TNFAIP3、TOB1、TOX4、TP63、TRERF1、TRIB 3、TRIM24、TRIM28、TRIM30、TRIP13、TRIP4、TRIP6、TRP53、TRP53BP 1、TRP63、TRPS1、TRPS1、TSC22D1、TSC22D2、TSC22D3、TSC22D4、TSHZ 1、TSHZ3、TTRAP、TUB、TULP4、TWIST1、TWIST2、TYSND1、UBE2W、UBN1、 UBP1、UBTF、UGP2、UHRF1、UHRF2、UNCX、USF1、USF2、UTF1、VDR、VEZF1、VGLL2、VSX1、WASL、WHSC1、WHSC2、WT1、WWP1、WWTR1、XBP1、YAF2、YY1、ZBED1、ZBED4、ZBTB1、ZBTB10、ZBTB16、ZBTB16、ZBTB17、ZBTB2、ZBTB20、ZBTB22、ZBTB25、ZBTB32、ZBTB38、ZBTB4、ZBTB43、ZBTB45、ZBTB47、ZBTB7A、ZBTB7B、ZBTB7C、ZCCHC8、ZDHHC13、ZDHHC16、ZDHHC21、ZDHHC5、ZDHHC6、ZEB2、ANK2ZEB2、ZFHX2、ZFHX3、ZFHX4、ZFP105、ZFPllO、ZFP143、ZFP148、ZFP161、ZFP192、ZFP207、ZFP219、ZFP238、ZFP263、ZFP275、ZFP277、ZFP281、ZFP287、ZFP292、ZFP35、ZFP354C、ZFP36、ZFP36L1、ZFP386、ZFP407、ZFP42、ZFP423、ZFP426、ZFP445、ZFP45 1、ATF5ZFP45 1、ZFP467、ZFP52、ZFP57、ZFP592、ZFP593、ZFP597、ZFP612、ZFP637、ZFP64、ZFP647、ZFP748、ZFP810、ZFP9、ZFP91、ZFPM1、ZFPM2、ZFX、ZHX2、ZHX3、ZIC1、ZIC2、ZIC3、ZIC4、ZIC5、ZKSCAN1、ZKSCAN3、ZMYND11、ZNF143、ZNF160、ZNF175、ZNF184、ZNF192、ZNF213、ZNF217、ZNF219、ZNF22、ZNF238、ZNF24、ZNF267、ZNF273、ZNF276、ZNF280D、ZNF281、ZNF292、ZNF311、ZNF331、ZNF335、ZNF337、ZNF33B、ZNF366、ZNF394、ZNF398、ZNF41、ZNF410、ZNF415、ZNF423、ZNF436、ZNF444、ZNF445、ZNF451、ZNF460、ZNF496、ZNF498、ZNF516、ZNF521、ZNF532、ZNF536、ZNF546、ZNF552、ZNF563、ZNF576、ZNF580、ZNF596、ZNF621、ZNF628、ZNF648、ZNF649、ZNF652、ZNF655、ZNF664、Examples include ZNF668, ZNF687, ZNF692, ZNF696, ZNF697, ZNF710, ZNF80, ZNF91, ZNF92, ZNRD1, ZSCAN10, ZSCAN16, ZSCAN20, ZSCAN21, ZXDC, and ZZZ3.

[0030] Also, as suitable transcription factors, 2210012G02Rik, Akap81, Appl2, Arid4b, Arid5b, Ashll, Atf7, Atm, C430014KllRik, Chd9, Dmtfl, Fos, Foxol, Foxpl, Hmboxl, Kdm5b, Klf2, Mga, Mill, M113, Myst4, Pcgf6, Rev31, Scml4, Scp2, Smarca2, Ssbp2, Suhw4, Tcf7, Tfdp2, Tox, Zbtb20, Zbtb44, Zebl, Zfml, Zfpl, Zfp319, Zfp329, Zfp35, Zfp386, Zfp445, Zfp518, Zfp652, Zfp827, Zhx2, Eomes, Arntl, Bbx, Hbpl, Jun, Mef2d, Mterfdl, Nfat5, Nfe212, Nrld2, Phf21a, Taf4b, Trf, Zbtb25, Zfp326, Zfp451, Zfp58, Zfp672, Egr2, Ikzf2, Tafld, Chracl, Dnajb6, Aplp2, Batf, Bhlhe40, Fosb, Histlhlc, Hopx, Ifihl, Ikzf3, Lass4, Lin54, Mxdl, Mxil, Prdml, Prfl, Rora, Rpa2, Sap30, Stat2, Stat3, Taf9b, Tbx21, Trpsl, Xbpl, Zeb2, Atf3, Cenpcl, Lass6, Rbl, Zbtb41, Crem, Fosl2, Gtf2b, Irf7, Maff, Nr4al, Nr4a2, Nr4a3, Obfc2a, Rbls, Rel, Rybp, Sral, Tgifl, Tnfaip3, Uhrf2, Zbtbl, Ccdcl24, Csda, E2f3, Epasl, HlfO, H2afz, Hifla, Ikzf5 4, Nsbpl, Piml, Rfc2, Swap70, Tfblm, 2610036LllRik, 5133400G04Rik, Apitdl, Blm, Brcal, Bripl, Cld, C79407, Cenpa, Cfll, Clspn, Ddxl, Dsccl, E2f7, E2f8, Ercc61, Ezh2, Fenl, Foxml, Genl, Gsg2, H2afx, Hdacl, Hdgf, Hells, Histlhle, Hist3h2a, Hjurp, Hmgb2, Hmgb3l, M8, Kif22, Kif4, Ligl, Lmo2, Lnp, Mbd4, Mcm2, Mcm3, Mcm4, Mcm5, Mcm6, Mcm7, Mybl2, Neil3, Nusapl, Orc61, Polal, Pola2, Pole, Pole2, Polh, Pol r2f, Polr2j, Ppplr8, Prim2, Psmc3ip, Rad51, Rad51c, Rad541, Rfc3, Rfc4, Rnpsl, Rpal, Smarccl, Spic, Ssrpl, Taf9, Tfdpl, Tmpo, Topbpl, Trdmtl , Uhrfl, Wdhdl, Whscl, Zbpl, Zbtb32, Zfp367, Carl, Polg2, Atr, Lefl, Myc, Nucb2, Satbl, Tafia, Ift57, Apexl, Chd7, Chtf8, Ctnnbl, Etv3, M9, Myb, Mybbpla, Pms2, Preb, SpllO, Statl, Trp53, Zfp414, App, Cdk9, Ddbl, Hsf2, Lbr, Pa2g4, Rbmsl, Rfcl, Rfc5, Tada21, Tex261, and Xrcc6.

[0031] Proteins whose expression is intended to be increased also include chimeric antigen receptor (CAR) proteins and T cell receptor (TCR) proteins. Expression of these receptor proteins can increase the amount of antigen that can be targeted by T cells and further promote T cell activation.

[0032] In the present invention, antigens intended to be bound by a chimeric antigen receptor (CAR) or a T cell receptor (TCR) are not particularly limited, and examples thereof include CD19, CD20, CD22, CD30 (TNFRSF8), CD33, CD38, CD44, CD56, CD70, CD123 (IL3RA), CD138 (SDC1), CD160, CD171 (L1CAM), Lewis Y, NKG2D ligand, ROR1, SLAMF7 / CS1, B7H3, CAIX, and CD44. v6 / v7, CEA, EGFRvIII, EGP2, EGP40, EphA2, ErbB2(HER2), ErbB receptor family, ErbB3 / 4, HLA-A1 / MAGE1, HLA-A2 / NY-ESO-1, FR-a, FAP, FAR, GD2, GD3, HMW-MAA, ILllRa, IL13Ra2, N CAM, PSMA, TAG72, VEGFR-2, Axl, Met, 5b3, 5b1, TRAIL-R1 / TRAIL-R2, RANKL, Tenacin, EpCAM, CEA, gpA33, mucins such as MUC1, MUC13, MUC16, MUC17, TAG-72, EphA3, IGF1R, MAGE-Al (MAGEAl), MART-1 (MLANA), NY-ESO (CTAG1), WT1, BCMA (TNFRSF17), B7H6 (NCR3LG1), CAIX (CA9), CS1 (SLAMF7), EGFRvIII (EGFR, vIII deletion variant), EGP2, GP40 (EPCAM), Erb family members (ERBB1, ERBB2, ERBB3, ERBB4), FAP (FAP), fetal acetylcholine receptor (AChR), folate receptor alpha (FOLRl), folate receptor beta (FOLR2), GPC3, IL-13Ra2 (IL13RA2), kappa light chain (IGK), mesothelin (MSLN), prostate-specific membrane antigen (PSMA) (FOLH1), prostate stem cell antigen (PSCA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), and anaplastic lymphoma receptor tyrosine kinase (ALK).

[0033] The present invention also provides a vector comprising the polynucleotide of the present invention. The vector may be a viral vector such as an adenoviral vector or a lentiviral vector, or a non-viral vector such as a plasmid, and any vector used in the art may be used as appropriate.

[0034] The present invention also provides a cell comprising the vector of the present invention. The polynucleotide of the present invention can induce the expression of a protein in a stimulation-specific manner when a T cell is activated. Therefore, the cell of the present invention is particularly preferably a T cell. In a preferred embodiment, the cell of the present invention is a T cell expressing a chimeric antigen receptor (CAR) protein (CAR-T cell) or a T cell expressing a T cell receptor (TCR) protein that reacts to a specific antigen (TCR-T cell).

[0035] T cell receptors (TCRs) have antibody-like variable regions that can specifically bind to antigen-MHC complexes. TCR-T cells are engineered to carry a TCR gene that reacts to a specific antigen and are activated by binding to the antigen-MHC complex. Chimeric antigen receptors (CARs) are engineered receptors created by combining a target-binding domain that specifically recognizes an antigen with a TCR-derived intracellular domain via a transmembrane domain. CAR-T cells are activated by binding of the target-binding domain to the target.

[0036] Methods for producing CAR-T cells and TCR-T cells are well known in the art, and a person skilled in the art can easily produce them based on the description in this specification and common technical knowledge in the art.

[0037] In the context of the present invention, multiple chimeric antigen receptors (CARs) and T cell receptors (TCRs) with specificity for different antigens can be used, and the same T cell may express multiple CARs and / or TCRs, or multiple types of T cells may be used, each expressing a distinct CAR and / or TCR.

[0038] The present invention further provides a pharmaceutical composition comprising the polynucleotide of the present invention, the vector of the present invention, or the cell of the present invention. The pharmaceutical composition of the present invention may be for treating and / or preventing a disease selected from, but not limited to, cancer, autoimmune disease, infectious disease, inflammatory disease, graft-versus-host disease, and myocardial fibrosis. The prevention may be prevention of recurrence after treatment.

[0039] Cancers that can be treated and / or prevented using the pharmaceutical compositions of the present invention include, but are not limited to, lymphoma, lymphocytic leukemia, myeloma, myeloid leukemia, myelodysplastic syndrome, pancreatic cancer, brain / central nervous system cancer, liver cancer, lung cancer, colon cancer, breast cancer, ovarian cancer, fallopian tube cancer, gastric cancer, neuroblastoma, mesothelioma, prostate cancer, melanoma, esophageal cancer, peritoneal cancer, sarcoma, cervical cancer, endometrial cancer, head and neck cancer, bladder cancer, nasopharyngeal cancer, esophagogastric junction cancer, eye cancer, germ cell tumor, kidney cancer, salivary gland cancer, urothelial cancer, and the like.

[0040] Autoimmune diseases that can be treated and / or prevented using the pharmaceutical composition of the present invention include, but are not limited to, rheumatoid arthritis, systemic lupus erythematosus (SLE), myasthenia gravis, hemophilia, pemphigus vulgaris, type I diabetes, etc.

[0041] Infectious diseases that can be treated and / or prevented with the pharmaceutical composition of the present invention include, for example, infectious diseases caused by viruses, bacteria, fungi, etc., such as human immunodeficiency virus (HIV), cytomegalovirus, hepatitis B virus, hepatitis C virus, invasive aspergillus, and Mycobacterium tuberculosis.

[0042] The present invention provides a method for producing genetically modified cells, which comprises the step of introducing the polynucleotide of the present invention into T cells. The T cells are not particularly limited, but preferred embodiments include CAR-T cells and TCR-T cells.

[0043] Methods for introducing polynucleotides into T cells can be any method commonly used in the art, and include, but are not limited to, for example, incorporating the polynucleotide into a vector such as a viral vector, a plasmid vector, or a phage vector together with regulatory sequences such as a signal sequence, a polyA sequence, or a promoter sequence, a selection marker, and the like, and then introducing the polynucleotide into T cells. Examples of viral vectors include lentiviral vectors, retroviral vectors, adenoviral vectors, and adeno-associated viral vectors. When no virus is used, methods such as electroporation, transposon, and CRISPR can be used alone or in appropriate combination.

[0044] When the T cells are CAR-T cells or TCR-T cells, the methods of the present invention may further comprise, in addition to the step of introducing the polynucleotide of the present invention, a step of introducing a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) into the T cells. The step of introducing into the T cells may be a step of simultaneously introducing the polynucleotide encoding the chimeric antigen receptor (CAR) or the T cell receptor (TCR) and the polynucleotide of the present invention by introducing a single vector containing the polynucleotide encoding the chimeric antigen receptor (CAR) or the T cell receptor (TCR) and the polynucleotide of the present invention.

[0045] Alternatively, the step of transducing into T cells can be a step of separately transducing a first vector comprising a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) and a second vector comprising a polynucleotide of the present invention. The first vector and the second vector may be introduced into T cells simultaneously or at different times in different steps, and if introduced at different times, they may be introduced in any order.

[0046] The present invention also provides a method for treating and / or preventing a disease in a subject, comprising administering to the subject the above-described polynucleotide of the present invention, the vector of the present invention, the cell of the present invention, or the pharmaceutical composition of the present invention. Diseases that can be treated and / or prevented by the method of the present invention can be selected from, but are not limited to, cancer, autoimmune diseases, infectious diseases, inflammatory diseases, graft-versus-host disease, and myocardial fibrosis.

[0047] The present invention also provides a method for producing a stimulus-inducible gene expression promoter, characterized by linking an NFAT-binding sequence, an NR4A-binding sequence, and a minimal promoter. The order in which the NFAT-binding sequence and the NR4A-binding sequence are linked is not particularly limited; for example, the NR4A-binding sequence may be linked upstream of the NFAT-binding sequence, or the NR4A-binding sequence may be linked downstream of the NFAT-binding sequence. In the stimulus-inducible gene expression promoter of the present invention, a minimal promoter is linked downstream of the NFAT-binding sequence and the NR4A-binding sequence.

[0048] The NFAT-binding sequence and the NR4A-binding sequence may be directly linked, or may be linked with an interval of several bases, for example, 1 to 100 bases, for example, 5 to 80 bases, 10 to 70 bases, or 20 to 60 bases. Similarly, a minimal promoter may be directly linked to an NFAT-binding sequence or an NR4A-binding sequence, or may be linked with an interval of several bases, for example, 1 to 10 bases. In a preferred embodiment, the stimulus-inducible gene expression promoter of the present invention may comprise multiple NFAT-binding sequences, for example, 3 to 6 repeated NFAT-binding sequences, and multiple NR4A-binding sequences, for example, 6 to 10 repeated NR4A-binding sequences.

[0049] The present invention further provides a method for expressing or producing a protein using a promoter having an NFAT-binding sequence and an NR4A-binding sequence. By ligating a gene encoding a protein downstream of the stimulus-inducible gene expression promoter prepared as described above and introducing it into T cells, the protein encoded by the gene located downstream of the stimulus-inducible gene expression promoter of the present invention can be expressed in a T cell stimulation-dependent manner. The above protein expression method can be achieved by contacting the above-described genetically modified cell of the present invention with, for example, a target antigen or a cell expressing the target antigen, and activating the genetically modified cell.

[0050] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples.

[0051] Example 1 Using green fluorescent protein (GFP), which is commonly used as a reporter gene, the expression of GFP downstream of different promoters induced by CAR stimulation was compared over time.

[0052] The structure of the promoter used in this example is shown in Figure 1. The NFAT promoter (NFATp) has a structure in which three NFAT binding sequences (NFAT-RE, GGAGGAAAAACTGTTTCATACAGAAGGCGT: SEQ ID NO: 1) are linked to an IL2 minimal promoter (SEQ ID NO: 5) containing a TATA sequence, and has the sequence of SEQ ID NO: 7.

[0053] The NR4A promoter (NR4Ap) has a structure in which eight NR4A binding sequences (NR4A-RE, AAAGGTCAC: SEQ ID NO: 3) are linked to a synthetic minimal promoter (SEQ ID NO: 6) containing a TATA sequence, and has the sequence of SEQ ID NO: 8.

[0054] The NFAT-NR4A promoter (NNp) has a structure in which, from upstream to downstream, eight NR4A response elements, three NFAT response elements, and an IL2 minimal promoter (sequence number 3) containing a TATA sequence are linked, and has the sequence of sequence number 9.

[0055] Human primary CD8+ T cells (STEMCELL technologies, ST-200-0164) were infected with a lentiviral vector expressing CD19CAR (referred to as CAR: derived from SEQ ID NO: 22) and a lentiviral vector (referred to as reporter: derived from SEQ ID NOs: 15-17) in which the gene of interest (GOI, in this example, GFP) was placed downstream of the promoter sequence under investigation. A map showing the structure of the vector using the NNp promoter of the present invention is shown in Figure 2.

[0056] Forty-eight hours after infection, the cells were cultured for 48 hours in X-VIVO15 medium (Lonza, 04-418Q) supplemented with 5% human serum and 100 μM 2-mercaptoethanol and containing puromycin (ThermoFisher, A1113803) at a final concentration of 4 μg / mL to select only cells into which the GFP gene had been introduced.

[0057] The obtained cells were used with a flow cytometer (CytoFLEX S) to check the proportion of CAR-expressing cells using mCherry as an indicator for each of the three promoters. As shown in Figure 3, the expression levels of CAR were equivalent, and therefore, the cells were considered to have equivalent cytotoxic activity.

[0058] The obtained cells were then co-cultured with CD19-positive Nalm-6 cells (RIKEN BRC, RCB1933) at an effector cell to Nalm-6 cell ratio (E:T) of 1:4. 24 hours, 48 ​​hours, and 72 hours later, GFP expression in mCherry-positive (CAR-positive: see SEQ ID NO: 20) cells was measured using a flow cytometer (CytoFLEX S), and the mean fluorescence intensity (MFI) was graphed.

[0059] As a result, as shown in Figure 4, GFP expression was significantly increased when the promoter of the present invention (NN-IL2miniP) was used compared to when the NFAT promoter (NFAT-IL2miniP) or the NR4A promoter (NR4A-SMP) was used. Furthermore, unlike the NFAT promoter, the promoter of the present invention continued to increase the amount of GFP expression even 72 hours after the start of co-culture.

[0060] [Example 2] An experiment similar to that of Example 1 was carried out, but with different E:T ratios (ratio of CAR-T cells to Nalm-6 cells), and the expression of GFP as a reporter was compared between the case where the NFAT promoter was used and the case where the promoter of the present invention (NR4A-NFAT promoter) was used.

[0061] The CAR and reporter (only derived from SEQ ID NOs: 15 and 17) were infected into human primary CD8+ T cells (STEMCELL technologies, ST-200-0164) and selected with puromycin.

[0062] The obtained cells were used with a flow cytometer (CytoFLEX S) to check the proportion of CAR-expressing cells using mCherry as an indicator for the two promoters. As shown in Figure 5, the expression levels of CAR were equivalent, and therefore, the cells were considered to have equivalent cytotoxic activity.

[0063] Next, 0.5 × 10 5 0.5 × 10 Nalm-6 cells (target, T) were added to CAR-T cells (effector, E) per well. 5 1 x 10 per well 5 pcs / well, 2 x 10 5 pcs / well, 4 x 10 5 Pieces / well, 8 x 10 5 Pieces / well, 16 x 10 5 mCherry-positive (SEQ ID NO: 20) cells (CAR-positive cells) were co-cultured with Nalm-6 at effector cell to target cell ratios (E:T) of 1:1 (100%), 1:2 (50%), 1:4 (25%), 1:8 (12.5%), 1:16 (6.25%), and 1:32 (3.125%), respectively, and the mean fluorescence intensity (MFI) indicating GFP expression in mCherry-positive (SEQ ID NO: 20) cells (CAR-positive cells) after 24 hours, 48 ​​hours, and 72 hours was graphed. As a result, as shown in Figure 6, it was confirmed that GFP expression was significantly higher when the promoter of the present invention was used, and was more pronounced when the ratio of target cells to effector cells was high, and that the increased expression persisted even after 72 hours.

[0064] Example 3: Expression of IL-12, a factor promoting cancer immune function, was employed, and CAR stimulation-dependent IL-12 release was compared using three promoters with IL-12p40 (SEQ ID NO: 31). Primary human CD8+ T cells were infected with a viral vector (derived from SEQ ID NOs: 21-23) containing a CAR (denoted as YC) and an IL-12 p40 expression cassette. A map showing the vector structure when the NN promoter of the present invention was used is shown in Figure 7.

[0065] After infection, selection was performed with puromycin in the same manner as in Example 1 (only control YC and uninfected CD8T were not treated with puromycin), and then CAR-T cells (1 × 10 5 cells / well), and CD19-positive Nalm-6 cells (CD19-deficient Nalm-6 cells or no target cells were used as controls). 5 The cells were co-cultured at a ratio of 1:4 per well (E:T = 1:4), and IL-12p40 in the culture supernatant after 72 hours was measured by ELISA (BD Human IL-12 (p40) ELISA Set).

[0066] CD19-deficient Nalm cells were generated by electroporating Nalm-6 cells with Cas9 protein (TrueCut, A36496, ThermoFisher) and gRNA (CUGUGCUGCAGUGCCUCAA: SEQ ID NO: 35, ThermoFisher) using a Nucleofector (Lonza) and then isolating CD19-negative cells using a cell sorter (FACSMelody, BD).

[0067] The results showed that the use of the promoter of the present invention (NNp) significantly increased IL-12p40 expression compared to the NFAT promoter (NFATp) and the NR4A promoter (NR4Ap) (Figure 8). IL-12p40 expression was low when CD19-deficient Nalm-6 cells were used or when target cells were not present, confirming that it was dependent on CAR-T cells activated by CD19 binding. Furthermore, the low expression of IL-12p40 from CAR-T cells lacking the IL-12p40 expression cassette confirmed that endogenous IL-12p40 expression was not detected.

[0068] Example 4: CAR-T cells are known to release TNFα in a manner dependent on CAR stimulation (J Immunol Vol. 199, No. 1, 348-362, 2017; https: / / journals.aai.org / jimmunol / article / 199 / 1 / 348 / 109491 / Comprehensive-Approach-for-Identifying-the-T-Cell). In this example, a gene (SEQ ID NO: 13) encoding etanercept (SEQ ID NO: 33), which binds to and inhibits TNFα, was linked downstream of three promoters, and the TNFα inhibitory effect of etanercept, whose expression increases in a manner dependent on CAR stimulation, was measured.

[0069] Human primary CD8+ T cells were infected with a viral vector containing a CAR (denoted YC) and an etanercept expression cassette (SEQ ID NOs: 27-29) and selected with puromycin (control CD8+ T cells not infected with the viral vector were not treated with puromycin). They were then co-cultured with CD19-positive Nalm-6 cells (CD19-deficient Nalm-6 cells or no target cells were used as controls) at an E:T ratio of 1:4. After 72 hours, the culture was added to TNF-α reporter cells (Invivogen, HEK-Blue TNFα cells). After 24 hours, placental alkaline phosphatase (SEAP) secreted in response to TNFα was measured, and TNFα activity in the culture supernatant was quantified relative to the response of the TNF-α reporter cells to recombinant TNFα.

[0070] As a result, as shown in Figure 9, when the promoter of the present invention (NNp) was used, TNFα activity in the culture supernatant was significantly lower than when the NFAT promoter was used, indicating that etanercept expression was dependent on CAR stimulation. Furthermore, when target cells did not express CD19 (CD19KO) or when target cells were not present, TNFα activity was extremely low, indicating no effect of etanercept expression. Even when the IL-1 inhibitor anakinra (IL1RA) was linked downstream of the promoter of the present invention and expressed in a CAR-stimulation-dependent manner, no inhibitory effect on TNFα activity was observed.

[0071] Example 5: CAR-T cells themselves release IL-1 upon activation (Nature Medicine, 24, 731-738 (2018); https: / / www.nature.com / articles / s41591-018-0041-7). It has also been reported that activated CAR-T cells cause surrounding cells to release IL-1 (Nature Immunology, 21, 65-74 (2020); https: / / www.nature.com / articles / s41590-019-0559-y). In this example, the inhibitory effect of anakinra on IL-1β released by CAR-T cells in a CAR stimulation-dependent manner was measured by linking a gene encoding anakinra downstream of three promoters.

[0072] As in Example 4, a viral vector containing an IL1RA (anakinra) expression cassette (sequences 24-26) was used. Nalm-6 cells (CD19-deficient Nalm-6 cells or no target cells were used as controls) were cocultured at an E:T ratio of 1:4. After 72 hours, the culture was added to IL-1β reporter cells (Invivogen, HEK-Blue IL-1β cells). After 24 hours, placental alkaline phosphatase (SEAP) secreted in response to IL-1β was measured, and IL-1β activity in the culture supernatant was quantified using the response of the IL-1β reporter cells to recombinant IL-1β as a reference.

[0073] As a result, as shown in Figure 10, when the promoter of the present invention (NNp) was used, the IL-1β activity in the culture supernatant was significantly lower than when the NFAT promoter was used, indicating that anakinra was expressed in a CAR stimulation-dependent manner.

[0074] Furthermore, when target cells did not express CD19 (CD19KO) or when target cells were absent (-), IL-1β activity was extremely low, and no effect of anakinra expression was observed. Even when etanercept, a TNFα inhibitor, was linked downstream of the promoter of the present invention and expressed in a CAR-stimulation-dependent manner, no inhibitory effect on IL-1β activity was observed.

[0075] All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety.

Claims

1. A polynucleotide comprising a promoter having an NFAT binding sequence and an NR4A binding sequence.

2. The polynucleotide according to claim 1, wherein the NFAT binding sequence is the base sequence shown in SEQ ID NO: 2 or a complementary sequence thereof, and the NR4A binding sequence is the base sequence shown in SEQ ID NO: 4 or a complementary sequence thereof.

3. The polynucleotide according to claim 1, wherein the NFAT binding sequence is the base sequence shown in SEQ ID NO: 1 or a complementary sequence thereof, and the NR4A binding sequence is the base sequence shown in SEQ ID NO: 3 or a complementary sequence thereof.

4. The polynucleotide of claim 1, wherein an NR4A binding sequence is present upstream of the NFAT binding sequence.

5. The polynucleotide of claim 1, comprising 3 to 6 repeated NFAT binding sequences and 6 to 10 repeated NR4A binding sequences.

6. The polynucleotide according to claim 1, which has a gene encoding a protein downstream of the promoter.

7. The polynucleotide of claim 6, wherein the protein is selected from the group consisting of a cytokine, a chemokine, a growth factor, an antibody, an agonist, an antagonist, a neuropeptide, a transcription factor, a chimeric antigen receptor (CAR), and a T cell receptor (TCR).

8. A vector comprising the polynucleotide of claim 1.

9. A cell comprising the vector of claim 8.

10. The cell of claim 9, which is a T cell.

11. The cell of claim 8, which is a T cell expressing a chimeric antigen receptor (CAR) or a T cell receptor (TCR).

12. A pharmaceutical composition comprising the polynucleotide of claim 1, the vector of claim 8, or the cell of claim 9.

13. The pharmaceutical composition according to claim 12 for the treatment and / or prevention of a disease selected from cancer, an autoimmune disease, an infectious disease, an inflammatory disease, graft-versus-host disease, and myocardial fibrosis.

14. A method for producing a genetically modified cell, comprising the step of introducing the polynucleotide of claim 1 into a T cell.

15. The method of claim 14, further comprising the step of introducing into the T cell a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR).

16. The method of claim 15, wherein the step of introducing into the T cells is carried out using: (i) a single vector comprising a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) and the polynucleotide of claim 1; or (ii) a first vector comprising a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) and a second vector comprising the polynucleotide of claim 1.

17. A method for producing a stimulus-inducible gene expression promoter, comprising linking an NFAT-binding sequence, an NR4A-binding sequence, and a minimal promoter.

18. A method for expressing a protein using a promoter having an NFAT binding sequence and an NR4A binding sequence.

Citation Information

Patent Citations

  • Genetically engineered cells and their applications

    JP2021523743A